Compare · GRNA vs NVS
GRNA vs NVS
Side-by-side comparison of GreenLight Biosciences Holdings PBC (GRNA) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GRNA and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS carries a market cap of $279.39B.
- NVS has more recent analyst coverage (25 ratings vs 2 for GRNA).
- Company
- GreenLight Biosciences Holdings PBC
- Novartis AG
- Price
- $0.30-0.20%
- $146.50-1.72%
- Market cap
- -
- $279.39B
- 1M return
- -
- +0.71%
- 1Y return
- -
- +24.12%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 0
- Recent ratings
- 2
- 25
GreenLight Biosciences Holdings PBC
GreenLight Biosciences Holdings, a biotechnology company, manufactures and sells ribonucleic acid (RNA) products for human health and agriculture applications. Its products for human health include mRNA vaccines and therapeutics; and agricultural RNA products to protect honeybees and crops. The company was founded in 2008 and is headquartered in Medford, Massachusetts.
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest GRNA
- SEC Form 15-12G filed by GreenLight Biosciences Holdings PBC
- SEC Form SC 13D/A filed by GreenLight Biosciences Holdings PBC (Amendment)
- SEC Form SC 13D/A filed by GreenLight Biosciences Holdings PBC (Amendment)
- GreenLight Biosciences Holdings PBC filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (Amendment)
- SEC Form SC 13D/A filed by GreenLight Biosciences Holdings PBC (Amendment)
- SEC Form 4 filed by Kodiak Venture Partners Iii Lp
- SEC Form 3: New insider Kodiak Venture Partners Iii Lp claimed ownership of 9,809,895 shares
- SEC Form 4 filed by Clarke Dennis A.
- SEC Form 4 filed by Anderson Eric Senior
- SEC Form 4 filed by Cummings Foundation, Inc.
Latest NVS
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- Novartis AG upgraded by Argus with a new price target
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- SEC Form S-8 filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form IRANNOTICE filed by Novartis AG
- SEC Form 20-F filed by Novartis AG
- Citigroup initiated coverage on Novartis AG